In early November, Pfizer and its German partner, BioNtech, released results of their ongoing trial for a COVID-19 vaccine, showing very positive early results of 90% efficacy rates. Shortly after, Moderna followed suit with similarly positive results from their COVID vaccine trial. In the midst of a second wave of increasing case counts and the communal weariness from ongoing (and increasing) restrictions and lockdowns, the good news couldn’t have come soon enough. Investors around the globe were quick to hitch their wagons to the idea of a vaccine-enabled return to gatherings, events, traditional business functions and economic activity.
To continue reading please click HERE
From tariffs and trade disputes to rising interest rates and stubborn inflation, this month's update…
August was a strong month for global markets, but uncertainty remains. Learn about the key…
Global events continue to shape the economic outlook, creating new opportunities and risks for investors.…
How are inflation, interest rates and global events influencing markets? While global equity markets were…
Global markets are climbing but rising inflation, high energy costs, and cautious consumers tell a…